Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada living with active secondary progressive multiple sclerosis (SPMS). Teva Canada will take over the promotion, distribution, and commercialization of the oral MS therapy in Canada. The companies say…

Experimental Bruton’s tyrosine kinase (BTK) inhibitors, such as tolebrutinib or evobrutinib, are as effective as the approved therapy Aubagio (teriflunomide) at preventing relapses in people with relapsing forms of multiple sclerosis (MS), according to a review of published studies. The review found the therapies to be…

Years before a diagnosis of multiple sclerosis (MS), people who later develop the disease have more doctor visits and hospitalizations for sensory, nervous system, and muscle problems than people in the general population, according to a recent study. The findings support the idea of an early phase of MS,…

Closely following a Mediterranean diet — which involves eating lots of fruits, vegetables, and whole grains, and limiting intake of processed and sugary foods — is associated with a significantly lower risk of developing multiple sclerosis (MS), a large Swedish study has found. The benefits, however, were seen mostly…